<i>Roseburia hominis</i> improves host metabolism in diet-induced obesityOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study investigated Roseburia hominis as a novel candidate probiotic (next-generation live biotherapeutic) for treating obesity and related metabolic disease. The researchers first examined how R. hominis abundance related to obesity status, then tested whether supplementing R. hominis could prevent metabolic disturbances in a diet-induced obesity model. They also explored a possible mechanism involving nicotinamide riboside production and Sirtuin1/mTOR signaling.
Who was studied?
The abstract describes stool samples compared between obese subjects and lean controls, indicating a human cohort used to establish the association between R. hominis abundance and body mass index and serum triglycerides. The interventional portion of the study was conducted in mice fed a high-fat diet to model diet-induced obesity. Specific numbers of human subjects or mice, and demographic details, are not given in the abstract.
What were the most important findings?
Roseburia hominis was depleted in the stool of obese subjects compared with lean controls, and its abundance was negatively correlated with body mass index and serum triglycerides. In high-fat-diet mice, supplementing R. hominis prevented body weight gain, corrected glucose and lipid metabolism disorders, prevented fatty liver, inhibited white adipose tissue expansion, and reduced brown adipose tissue whitening, while boosting lean-associated microbial species. These effects were linked in part to R. hominis production of nicotinamide riboside and upregulation of the Sirtuin1/mTOR signaling pathway.
What are the greatest implications of this study?
The findings position Roseburia hominis as a promising next-generation live biotherapeutic candidate for preventing obesity and metabolic disease. Because its depletion tracks with obesity and adverse metabolic markers in humans, restoring this commensal species could represent a targeted microbiome-based strategy rather than a broad-spectrum probiotic approach. The nicotinamide riboside and Sirtuin1/mTOR mechanism offers a specific pathway for further mechanistic and translational research.